The NHS will invest nearly $7 million in AI tools to enhance prostate MRI performance and early cancer detection.
Key Details
- 1The NHS is allocating almost $7 million to AI solutions for prostate MRI, as part of a wider $20 million investment.
- 2Lucida Medical will receive over $3 million, and Quibim (Spain) will get $3.5 million to deploy prostate AI tools.
- 3Quibim's QP-Prostate software will be rolled out in seven English hospitals over two years.
- 4The project aims to increase the rate of early-stage prostate cancer diagnoses from 50% to 75% by 2028.
- 5Prostate cancer is the most common cancer in UK men, with over 52,000 new cases and 12,000 deaths annually.
Why It Matters
Investing in AI-enhanced MRI interpretation could significantly increase early detection rates of prostate cancer, potentially improving patient outcomes. This major NHS rollout signals strong institutional confidence in AI’s role in clinical radiology practice.
Source
Radiology Business
Related News
•Radiology Business
Women's Uncertainty About AI in Breast Imaging May Limit Acceptance
Many women remain unclear about the role of AI in breast imaging, creating hesitation toward its adoption.
•Radiology Business
AI Tool Detects Elusive Epilepsy Lesions Missed by Radiologists
Researchers developed an AI tool that identifies focal cortical dysplasia on imaging, aiding diagnosis and surgical planning for epilepsy.
•Health Imaging
St. Luke's Network Deploys AI Radiology Tool Systemwide
St. Luke’s University Health Network has implemented Gleamer’s BoneView AI tool for bone abnormality detection across all its locations.